New theranostic nanobody for CMS4 colorectal cancer: selective PET imaging and targeted radiotherapy
| Reference number | |
| Coordinator | Region Uppsala - PET Centrum Bild och funktionsmedicinskt centrum (UAS BFC) |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | April 2021 - June 2025 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
In the ColoSelect project a new and specific diagnostic imaging approach for colorectal cancer using positron emission tomography is developed. A nanobody, labelled with a PET-radionuclide, with affinity to platelet derived growth factor beta (PDGFRbeta) is developed to be used as a biomarker for the aggressive CMS4 subtype of colorectal cancer (concensus molecular subtype). Early classification and detection of CMS4 may lead to better treatment.
Expected effects and result
A radioactive PET tracer is available for use in a First-In-Man PET study in patients with colorectal cancer. The radioactive nanobody allows visualization and quantification of PDGFRbeta expression in the tumour which could be used for classification according to the CMS system.
Planned approach and implementation
The project is based on radiochemistry and preclinical PET validation of a library of radiolabelled nanobodies. The radiolabelled nanobody which show optimal characteristics as an in vivo biomarker for PDGFRbeta is validated and qualified for use in a follow-up clinical PET study in patient´s with colorectal cancer. This study is outside the budget for the ColoSelect project.